Chelsea Therapeutics: Caution Warranted
On February 18th 2014, Chelsea Therapeutics International, Ltd. (NASDAQ:CHTP) that the U.S. Food and Drug Administration (FDA) granted accelerated approval of NORTHERATM (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension (NOH). NORTHERA represents the only therapy approved by the FDA, which demonstrates symptomatic benefit in patients with NOH. This autonomic disorder manifests with symptoms including dizziness, lightheadedness, blurred vision, fatigue, poor concentration and fainting episodes. The pathophysiology of NOH is caused by an endogenous insufficiency to produce and release sufficient levels of norepinephrine upon standing. The disorder affects an estimated 80,000 to 150,000 individuals in the United States. While this is a major accomplishment for Chelsea shareholders and patients with NOH, there remains...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|